6 results match your criteria: "IASO Group Hospitals[Affiliation]"

Cefepime/zidebactam is in clinical development for the treatment of carbapenem-resistant Gram-negative infections. MICs of cefepime/zidebactam (1:1) and comparators against Enterobacterales (n = 563), Pseudomonas (n = 172) and Acinetobacter baumannii (n =181) collected from 15 Greek hospitals (2014-2018) were determined by reference broth microdilution method. The isolates exhibited high carbapenem resistance rates [(Enterobacterales (75%), Pseudomonas (75%) and A.

View Article and Find Full Text PDF

Carbapenem resistant (CRAB) represents one of the most challenging pathogens in clinical settings. Colistin is routinely used for treatment of infections by this pathogen, but increasing colistin resistance has been reported. We obtained 122 CRAB isolates from nine Greek hospitals between 2015 and 2017, and those colistin resistant (ColR; = 40, 32.

View Article and Find Full Text PDF

Pneumococcal puerperal mastitis in a lactating mother.

Access Microbiol

April 2019

Central Laboratories, IASO Gynecology, Maternity and Pediatric Hospital, IASO Group Hospitals, Athens, Greece.

Introduction: A case of pneumococcal mastitis in a breast-feeding mother 6 months postpartum is described. Mastitis is usually caused by . A review of the literature from 1950 to March 2018 revealed only four other cases in which the causative organism was .

View Article and Find Full Text PDF
Article Synopsis
  • TP-6076 is a synthetic antibiotic that targets bacterial protein synthesis, specifically tested against carbapenem-resistant Acinetobacter baumannii from 13 Greek hospitals.
  • The study involved 121 bacterial isolates, where TP-6076 showed low minimum inhibitory concentrations (MICs) of 0.03 mg/L and 0.06 mg/L, indicating strong effectiveness.
  • Compared to other antibiotics like tigecycline and minocycline, TP-6076 demonstrated superior activity against resistant strains, while its effectiveness remained consistent regardless of colistin susceptibility.
View Article and Find Full Text PDF

Background: Cefiderocol (S-649266), a siderophore cephalosporin, utilizes a novel mechanism of entry into the periplasmic space of Gram-negative bacteria and is broadly stable to ESBLs and carbapenemases.

Methods: A collection of carbapenem-resistant Gram-negative bacteria isolated from clinical specimens in 18 Greek hospitals was tested for susceptibility to cefiderocol, meropenem, ceftazidime, cefepime, ceftazidime/avibactam, ceftolozane/tazobactam, aztreonam, amikacin, ciprofloxacin, colistin and tigecycline. Broth microdilution plates were used to determine MICs.

View Article and Find Full Text PDF

An infection of the lower urinary tract associated with an extremely unpleasant odour due to in an otherwise healthy 5-year-old boy is described herein. Interestingly, imaging examination revealed the presence of a bladder diverticulum. Routine microbiological examination based on Gram staining, colony morphology and catalase reactivity suggested that the responsible pathogen could belong either to staphylococci, α-haemolytic streptococci or enterococci, which are more common urine isolates.

View Article and Find Full Text PDF